CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 742 enrolled
Drug / intervention
Voglibosedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01993927
NCT01993927N/ACompleted

Voglibose Tablets 0.2 / Voglibose Oral Disintegrant (OD) Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"

Takeda·observational·Posted Nov 25, 2013·Updated Dec 4, 2018

In Brief

An observational study evaluating Voglibose for Impaired Glucose Tolerance. Completed, enrolled 742 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the safety and efficacy of long-term use of Voglibose (Basen) to prevent progression to type 2 diabetes mellitus in participants with impaired glucose tolerance in the routine clinical setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 25, 2013
Enrollment StartNov 18, 2009
Primary CompletionAug 31, 2013
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 12.6 years ago

Interventions

Voglibosedrug

Voglibose Tablets / Voglibose OD Tablets